Stock Analysis
Evotec (ETR:EVT) Third Quarter 2024 Results
Key Financial Results
- Revenue: €184.9m (down 5.8% from 3Q 2023).
- Net loss: €39.6m (loss widened by 1.7% from 3Q 2023).
- €0.22 loss per share (further deteriorated from €0.22 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Evotec Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates by 57%.
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Performance of the market in Germany.
The company's shares are up 11% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Evotec that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if Evotec might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:EVT
Evotec
Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
